JAB-3068

DRUG3 trials

Sponsors

Jacobio Pharmaceuticals Co., Ltd.

Conditions

Advanced Solid TumorEsophageal CancerEsophageal Squamous Cell CarcinomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaNon Small Cell Lung CancerNon-small Cell Lung CancerOther Metastatic Solid Tumors

Phase 1

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

CompletedNCT03518554

Jacobio Pharmaceuticals Co., Ltd.Esophageal Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer +1

Start: 2018-04-23End: 2022-02-03Updated: 2024-12-16

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

CompletedNCT03565003

Jacobio Pharmaceuticals Co., Ltd.Esophageal Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer +1

Start: 2018-11-20End: 2023-01-31Updated: 2024-09-25

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

CompletedNCT04721223

Jacobio Pharmaceuticals Co., Ltd.Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma +1

Start: 2021-04-26End: 2023-12-29Updated: 2024-09-19